Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update
May 07, 2020 16:01 ET
|
Eloxx Pharmaceuticals
Completing our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority Preclinical studies advancing in autosomal dominant polycystic kidney disease (ADPKD) and...
Eloxx Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
April 13, 2020 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis
March 25, 2020 09:00 ET
|
Eloxx Pharmaceuticals
Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic Cystic Fibrosis patients, especially those with nonsense mutations, are at increased...
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update
March 05, 2020 16:00 ET
|
Eloxx Pharmaceuticals
Topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 in H1 2020 Realignment strengthens commitment to Cystic Fibrosis and strategic flexibility by extending cash runway through the...
Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources
February 26, 2020 16:00 ET
|
Eloxx Pharmaceuticals
Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization of Cystic...
Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™
January 14, 2020 14:30 ET
|
Eloxx Pharmaceuticals
Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported...
Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020
December 18, 2019 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019
November 19, 2019 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019
November 18, 2019 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
November 07, 2019 10:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...